The TAILORx trial then validated its clinical utility in node negative ER-positive HER2-negative BC, classifying patients into three risk groups according to different cut-offs: low (RS = 0–11), intermediate (RS = 12–25) and high (RS = 26–100)20. This evidence concerns the gene ERBB2 and breast cancer.